Strategies to Advance Diversity and Accelerate Enrollment in Oncology Clinical Trials

Noelle Gaskill, MBA, ACRP-CP is a research executive with over 25 years of experience spanning across the industry from sites to biotech. In her tenure leading large-scale research organizations, she successfully deployed novel just-in-time recruitment models, patient matching powered by AI, and has developed site technology - all with the purpose of reducing the burden on the site. Today, she leads the Tempus TIME Network - a perfect fit for her personal motivator of providing novel therapeutics to all patients close to home.

Jonathan is an early team member at Tempus where he currently serves as Vice President, Generative AI and Head of Tempus One, focused on search, artificial intelligence, and provider-facing tools. He has been building and delivering scaled software products across both the consumer and enterprise space for over 15 years in a number of industries including healthcare, life science, telemedicine, genomics, mobile commerce, security, human capital, and talent acquisition.

Dr. Chelsea Osterman is a medical oncologist and senior medical director with the Tempus TIME program. She completed her residency in internal medicine at the University of Pennsylvania and fellowship in oncology at the University of North Carolina. Prior to joining Tempus, Dr. Osterman worked as an oncologist in Asheville, NC and in the Real-World Evidence division at Flatiron Health. She is currently supporting the TIME trial network and leading multiple generative AI initiatives at Tempus.

Dr. Maria Berezina is the VP of Real World Data at Tempus, where she oversees clinical data structuring, data model development, and the RWD/RWE analytics. With a decade of experience in oncology analytics, she provides business and research insights to large pharmaceutical companies, biotechs, start-ups, investment funds, and insurance providers. Over the past five years, she has built and led RWD analytics and data science teams, overseeing numerous retrospective studies for life science partners. Her blend of technical expertise, deep knowledge of clinical care in oncology, and experience in RWE generation ensures that Tempus' multi-modal RWD product aligns with life science research goals. She holds a bachelor's degree in Electrical Engineering from the University of Massachusetts Lowell and a doctoral degree in Biomedical Engineering from the Harvard-MIT Division of Health Science and Technology.

Dr. Kathleen Burke is a Senior Director of Computational Biology supporting the Tempus strategic alliances. This team collaborates across companies to drive multimodal analysis that accelerates projects throughout the discovery pipeline by enhancing trial design, broadening biomarker testing, investigating combination opportunities, identifying novel targets, and more. Before coming to Tempus, Kathleen worked at AstraZeneca in the bioinformatics group supporting the Early Oncology Translational Medicine, analyzing molecular data for Hematology drug teams with a focus on determining mechanisms of resistance to Acalabrutinib. She received her PhD in Biomedical Engineering from the University of Rochester and performed post-doctoral research at Memorial Sloan Kettering Cancer Center, understanding the genetic landscape of rare breast/uterine carcinomas.